The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years after being declared in shortage by the Food and Drug Administration (FDA).

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different doses being listed in shortage at various times.

It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.